CAGE Bio has announced positive topline results from its Phase 2b, double-blinded, dose-ranging trial of CGB-500, an investigational topical drug for atopic dermatitis (AD).
The study met primary and secondary endpoints, demonstrating best-in-class efficacy, rapid itch relief, and a strong safety profile.
Key Phase 2b Results
- Patient population: 180 patients ≥12 years old, across 16 US sites.
- Disease severity: 85% moderate, 9% mild, 6% severe. All had <10% affected body surface area (BSA).
- Efficacy outcomes:
- 59% achieved Investigator’s Global Assessment (IGA) treatment success (Clear or Almost Clear, ≥2-grade improvement).
- 71% experienced a ≥4-point improvement in worst itch (PP-NRS).
- 35% achieved complete itch resolution (0 itch score). - Benchmarking: Outcomes exceeded reported results for other topical AD therapies.
- Safety: Well tolerated with no new or unexpected safety signals.
Expert Commentary
Dr. Justin Ko, Board-Certified Dermatologist and SAB Chair, CAGE Bio:
“Patients with moderate-to-severe AD and low BSA involvement have limited topical options. CGB-500 may provide a safe, localized alternative to systemic drugs. Rapid itch relief and strong disease clearance rates make this highly attractive.”
Dr. Samir Mitragotri, Inventor of the Ionic Liquid Platform:
“Ionic liquid technology enables local drug delivery with systemic-like efficacy but a topical safety profile. This advantage is now translating into clear patient benefit.”
Dr. Nitin Joshi, CEO, CAGE Bio:
“These results mark an important milestone for CAGE Bio and patients with AD. We are moving quickly toward Phase 3 trials and potential registration.”
Why It Matters
- High unmet need: In the US, 6.6 million people suffer from moderate-to-severe AD, most with <10% BSA involvement. Current topical therapies often fall short, and systemic drugs are frequently prescribed despite localized disease.
- Potential shift in treatment: CGB-500 could become a topical, high-efficacy alternative for this underserved patient population.
Next Steps
- Full data will be presented at an upcoming scientific congress.
- Phase 3 development planned to advance rapidly.
About CAGE Bio
CAGE Bio is a biotechnology company developing ionic liquid–based therapies for immune-mediated skin diseases. Its pipeline includes clinical and preclinical assets targeting high-incidence dermatological conditions.
